60 DEGREES PHARMACEUTICALS LLC (SXTP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.92-1.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SXTP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Achieve profitability by 2028 through continued commercial growth in malaria prevention and obtaining supplemental FDA indication for babesiosis.
Stated in 2 of last 2 quarters. Revenue declined from $437,602 in 2025-Q3 to $207,898 in 2026-Q2, with operating losses persisting (operating income negative $2.3M to negative $2.3M). Management's target for profitability in 2028 relies on commercial growth and supplemental indications, but recent financials show declining revenue and ongoing losses, indicating limited progress toward near-term profitability.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Targeting profitability in 2028 based on: Continued commercial growth in malaria prevention and achieving supplemental indication for babesiosis”
“Targeting profitability in 2028 based on: Continued commercial growth in malaria prevention and achieving supplemental indication for babesiosis”
Complete clinical trials and submit a New Drug Application for tafenoquine for babesiosis by the first quarter of 2028.
Stated in 2 of last 2 quarters. The company is conducting clinical trials for tafenoquine in babesiosis with interim analyses planned by late 2026 and aims for NDA submission by Q1 2028. No revenue or income impact yet from this program, so progress is in clinical development stage with trajectory consistent with stated regulatory timeline.
“Plan to submit NDA for tafenoquine babesiosis indication by Q1 2028 pending trial outcomes”
“Plan to submit NDA for tafenoquine babesiosis indication by Q1 2028 pending trial outcomes”
Secure funding through private placement offerings to support working capital and general corporate purposes.
Newly stated in 2026-Q3. The company completed a private placement raising approximately $1.0 million to fund operations. Given ongoing operating losses and negative cash flow, this capital raise aligns with management's stated need to support working capital, indicating delivery on this funding priority.
“Entered into private placement agreements to raise approximately $1.0 million for working capital and general corporate purposes.”
Control operating losses and negative cash flow while progressing clinical and commercial activities.
Stated in 8 of last 8 quarters. Operating income remained negative, ranging from -$2.33M in 2025-Q3 to -$2.27M in 2026-Q2, with cash from operations negative between -$2.74M and -$2.23M in the last two quarters. The trajectory shows persistent operating losses and negative cash flow, indicating limited progress in reducing losses.
“Operating income negative $2.27M; cash from operations negative $2.23M”
“Operating income negative $2.09M; cash from operations negative $2.74M”
“Operating income negative $1.92M; cash from operations negative $1.69M”
“Operating income negative $2.33M; cash from operations negative $2.11M”
“Operating income negative $1.61M; cash from operations negative $1.45M”
“Operating income negative $1.91M; cash from operations negative $1.60M”
“Operating income negative $2.07M; cash from operations negative $1.64M”
“Operating income negative $2.12M; cash from operations negative $1.68M”
Strengthen board governance by appointing new directors to the Board.
Newly stated in 2026-Q2. The company appointed a new director to the Board in May 2026, demonstrating action on governance priorities. This is a single quarter mention with no further data on board changes, indicating initial delivery on this priority.
“The company appointed Eric Francois as a new director to the Board.”
Over the trailing year it converted 1.00x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
16 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.